Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors

Ivan Moiseev • 1 Sep 2020
EBMT 2020
Myeloproliferative Neoplasms

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of JAK1 and JAK2 inhibitors in patients undergoing allogeneic stem-cell transplantation (allo-HSCT) for BCR-ABL negative myeloproliferative neoplasms (MPNs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

1:01
Significance of MRD negativity in Ph-negative ALL
Ivan Moiseev • 1 Sep 2020
0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
1:29
Mutational profiles of MDS patients undergoing allo-HSCT
Ivan Moiseev • 30 Aug 2020

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals